Robert M. Jenner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Robert M. Jenner has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Gregor A. Stavrou
Department of General and Abdominal Surgery, Asklepios Hospital Barmbek, Hamburg, Germany; Semmelweis University Budapest, Campus Hamburg, Hamburg, Germany
3 shared publicationsKarl J. Oldhafer
Department of General and Abdominal Surgery, Asklepios Hospital Barmbek, Hamburg, Germany; Semmelweis University Budapest, Campus Hamburg, Hamburg, Germany
2 shared publications- Karl Jürgen Oldhafer
Asklepios Hospital Barmbek, Department of Surgery, Division for HPB Surgery, Hamburg, Germany; Asklepios Medical School, University of Semmelweis, Campus Hamburg, Germany
2 shared publications - Michael Linecker
Department of Surgery and Transplantation, Swiss HPB and Transplant Center, University Hospital Zurich, Zurich, Switzerland
2 shared publications - Mickael Lesurtel
Department of HPB Surgery and Liver Transplantation, APHP-Beaujon Hospital, Université Paris Cité, Paris, France
2 shared publications Pierre-Alain Clavien
Swiss HPB and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
2 shared publications
Latest Publications
- 1 November 2016
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 264 (5) , 763-771
The ALPPS Risk Score
To create a prediction model identifying futile outcome in ALPPS (Associating Liver Partition and Portal vein ligation for Staged hepatectomy) before stage 1 and stage 2 surgery. ALPPS is a 2-stage hepatectomy, which incorporates parenchymal transection at stage 1 enabling resection of extensive liver tumors. One of the major criticisms of ALPPS is the associated high mortality rate up to 20%. Using the International ALPPS Registry, a risk analysis for futile outcome (defined as 90-day or in-hospital mortality) was performed. Futility was modeled using multivariate regression analysis and a futility risk score formula was computed on the basis of the relative size of logistic model regression coefficients. Among 528 ALPPS patients from 38 centers, a futile outcome was observed in 47 patients (9%). The pre-stage 1 model included age 67 years or older [odds ratio (OR) = 5.7], and tumor entity (OR = 3.8 for biliary tumors) as independent predictors of futility from multivariate analysis. For the pre-stage 1 model scores of 0, 1, 2, 3, 4 and 5 were associated with futile risk of 2.7%, 4.9%, 8.6%, 15%, 24%, and 37%. The pre-stage 2 model included major complications (grade ≥ 3b) after stage 1 (OR = 3.4), serum bilirubin (OR = 4.4), serum creatinine (OR = 5.4), and cumulative pre-stage 1 risk score (OR = 1.9). The model predicted futility risk of 5%, 10%, 20%, and 50% for patients with scores of 3.9, 4.7, 5.5, and 6.9, respectively. Both models have an excellent prediction to assess the individual risk of futile outcome after ALPPS surgery and can be used to avoid futile use of ALPPS.
- 1 November 2016
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 264 (5) , 763-771
The ALPPS Risk Score
To create a prediction model identifying futile outcome in ALPPS (Associating Liver Partition and Portal vein ligation for Staged hepatectomy) before stage 1 and stage 2 surgery. ALPPS is a 2-stage hepatectomy, which incorporates parenchymal transection at stage 1 enabling resection of extensive liver tumors. One of the major criticisms of ALPPS is the associated high mortality rate up to 20%. Using the International ALPPS Registry, a risk analysis for futile outcome (defined as 90-day or in-hospital mortality) was performed. Futility was modeled using multivariate regression analysis and a futility risk score formula was computed on the basis of the relative size of logistic model regression coefficients. Among 528 ALPPS patients from 38 centers, a futile outcome was observed in 47 patients (9%). The pre-stage 1 model included age 67 years or older [odds ratio (OR) = 5.7], and tumor entity (OR = 3.8 for biliary tumors) as independent predictors of futility from multivariate analysis. For the pre-stage 1 model scores of 0, 1, 2, 3, 4 and 5 were associated with futile risk of 2.7%, 4.9%, 8.6%, 15%, 24%, and 37%. The pre-stage 2 model included major complications (grade ≥ 3b) after stage 1 (OR = 3.4), serum bilirubin (OR = 4.4), serum creatinine (OR = 5.4), and cumulative pre-stage 1 risk score (OR = 1.9). The model predicted futility risk of 5%, 10%, 20%, and 50% for patients with scores of 3.9, 4.7, 5.5, and 6.9, respectively. Both models have an excellent prediction to assess the individual risk of futile outcome after ALPPS surgery and can be used to avoid futile use of ALPPS.
- 26 January 2014
- Published by Springer Nature in Der Chirurg
- Vol. 85 (2) , 155-168
Zentrales Gallengangskarzinom (Klatskin-Tumor)
Das perihiläre Gallengangskarzinom (Klatskin-Tumor) ist ein seltener Tumor ausgehend von der extrahepatischen Gallengangsgabel. In Anbetracht der anatomisch engen Beziehung der Gallengangsgabel zu Leberparenchym, Pfortadergabel und auch Leberarterien bedeutet die Behandlung dieser Patienten eine große Herausforderung. Mit einer Inzidenz von 2 bis 4 Erkrankungen/100.000 Einwohner/Jahr ist eine Behandlung nur an Zentren sinnvoll, die über eine entsprechende Erfahrung verfügen. Histologisch liegt meist ein mäßig differenziertes Adenokarzinom vor, das diffus infiltrierend entlang der Gallenwege und Perineuralscheide nach proximal, aber auch nach distal wachsen kann. Als einzige kurative Option hat sich die radikale chirurgische Resektion von Gallenwegen, Gallengangsgabel en bloc mit Leberresektion und auch die Gefäßresektion durchgesetzt, dennoch ist das Erreichen eines proximalen und lateralen Sicherheitsabstands vom Tumor technisch problematisch. Perihilar cholangiocarcinoma or Klatskin tumors are a rare entity arising from the extrahepatic bile duct bifurcation. Considering the close anatomical relationship of the bile duct bifurcation with the portal vein bifurcation and hepatic arteries, surgical treatment is demanding. With an incidence of only 2–4 cases/100,000 population/year patients should be referred to a specialized center. The tumors are usually poorly differentiated adenocarcinomas growing diffusely along the duct and also the perineural sheath. Only radical surgery offers a curative option and currently surgical strategy usually consists of en bloc resection of the bile duct, extended liver resection and portal vein resection. Proximal and lateral safety margin R0 resections are technically very demanding procedures because of the local anatomy.
- 26 January 2014
- Published by Springer Nature in Der Chirurg
- Vol. 85 (2) , 155-168
Zentrales Gallengangskarzinom (Klatskin-Tumor)
Das perihiläre Gallengangskarzinom (Klatskin-Tumor) ist ein seltener Tumor ausgehend von der extrahepatischen Gallengangsgabel. In Anbetracht der anatomisch engen Beziehung der Gallengangsgabel zu Leberparenchym, Pfortadergabel und auch Leberarterien bedeutet die Behandlung dieser Patienten eine große Herausforderung. Mit einer Inzidenz von 2 bis 4 Erkrankungen/100.000 Einwohner/Jahr ist eine Behandlung nur an Zentren sinnvoll, die über eine entsprechende Erfahrung verfügen. Histologisch liegt meist ein mäßig differenziertes Adenokarzinom vor, das diffus infiltrierend entlang der Gallenwege und Perineuralscheide nach proximal, aber auch nach distal wachsen kann. Als einzige kurative Option hat sich die radikale chirurgische Resektion von Gallenwegen, Gallengangsgabel en bloc mit Leberresektion und auch die Gefäßresektion durchgesetzt, dennoch ist das Erreichen eines proximalen und lateralen Sicherheitsabstands vom Tumor technisch problematisch. Perihilar cholangiocarcinoma or Klatskin tumors are a rare entity arising from the extrahepatic bile duct bifurcation. Considering the close anatomical relationship of the bile duct bifurcation with the portal vein bifurcation and hepatic arteries, surgical treatment is demanding. With an incidence of only 2–4 cases/100,000 population/year patients should be referred to a specialized center. The tumors are usually poorly differentiated adenocarcinomas growing diffusely along the duct and also the perineural sheath. Only radical surgery offers a curative option and currently surgical strategy usually consists of en bloc resection of the bile duct, extended liver resection and portal vein resection. Proximal and lateral safety margin R0 resections are technically very demanding procedures because of the local anatomy.
- 11 December 2013
- Published by Wiley in World Journal of Surgery
- Vol. 38 (6) , 1504-1509
ALPPS for Patients with Colorectal Liver Metastases: Effective Liver Hypertrophy, but Early Tumor Recurrence
Background: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a promising method to increase resectability rates of liver tumors. Little has been published about oncological results so far. This report describes clinical evidence regarding a possible effect of ALPPS on tumor recurrence.Methods: Ten ALPPS procedures were performed for otherwise non‐resectable colorectal liver metastases. Seven of these ten patients had a follow‐up of at least 3 months and were analyzed for tumor recurrence.Results: Six of these seven patients had tumor recurrence to the liver. Three of seven patients presented with lung metastases, occurring earlier than liver metastases in two of three cases. One patient with a follow‐up of 3 months had no visible recurrent disease, but increasing carcinoembryonic antigen levels.Conclusions: The patient group operable only through ALPPS is at high risk for recurrence and early tumor progression. Still, this new method is the only chance for an oncological treatment strategy including a surgical approach and possibly better outcome.
- 11 December 2013
- Published by Wiley in World Journal of Surgery
- Vol. 38 (6) , 1504-1509
ALPPS for Patients with Colorectal Liver Metastases: Effective Liver Hypertrophy, but Early Tumor Recurrence
Background: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a promising method to increase resectability rates of liver tumors. Little has been published about oncological results so far. This report describes clinical evidence regarding a possible effect of ALPPS on tumor recurrence.Methods: Ten ALPPS procedures were performed for otherwise non‐resectable colorectal liver metastases. Seven of these ten patients had a follow‐up of at least 3 months and were analyzed for tumor recurrence.Results: Six of these seven patients had tumor recurrence to the liver. Three of seven patients presented with lung metastases, occurring earlier than liver metastases in two of three cases. One patient with a follow‐up of 3 months had no visible recurrent disease, but increasing carcinoembryonic antigen levels.Conclusions: The patient group operable only through ALPPS is at high risk for recurrence and early tumor progression. Still, this new method is the only chance for an oncological treatment strategy including a surgical approach and possibly better outcome.